Procyon Advisors’s Fulgent Genetics FLGT Stock Holding History

Procyon Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,683	Closed	-$201K	–	321
2022 Q2	$201K	Buy	3,683 +246	+7%	+$13.5K	0.04%	306
2022 Q1	$215K	Buy	+3,437	New	+$226K	0.04%	309

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Procyon Advisors's FLGT Position: Q3 2022 in Review

Procyon Advisors sold out of Fulgent Genetics (FLGT) in Q3 2022, closing a stake of 3,683 shares — an estimated $201K sold.

Procyon Advisors first reported a position in FLGT in Q1 2022 and held it in 2 quarters. The position peaked at $215K in Q1 2022. 235 funds tracked by Wall St. Rank hold FLGT as of Q3 2022.

Procyon Advisors reported no remaining Fulgent Genetics position as of Q3 2022 after selling out during the quarter.
Procyon Advisors sold 3,683 Fulgent Genetics shares in Q3 2022, an estimated $201K.
Procyon Advisors first reported a position in Fulgent Genetics in Q1 2022 and held it in 2 quarters.
Procyon Advisors's Fulgent Genetics position peaked at $215K in Q1 2022.
235 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2022.

Based on Procyon Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.